Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
8866 results about "Endocrinology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Endocrinology (from endocrine + -ology) is a branch of biology and medicine dealing with the endocrine system, its diseases, and its specific secretions known as hormones. It is also concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Specializations include behavioral endocrinology and comparative endocrinology.
System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
ActiveUS7060059B2Maintaining continuous, long-term control of the blood glucose concentrationsImprove performancePeptide/protein ingredientsDrug and medicationsInsulin infusionClosed loop
A closed loop therapy system for controlling a concentration of a substance, such as blood glucose concentration, in the body of a user. The system and method employ a sensor system that measures a glucose level in the body, a controller that uses the measured glucose levels to generate an output that can be used to automatically or manually control an intradermal insulin infusion system to set a constant or time-varying profile of target blood glucose concentrations in a user, and then infuse an appropriate amount of insulin into the body of the user so as to reach and maintain the target values of the blood glucose concentration.
Owner:BECTON DICKINSON & CO
Non-invasive tissue glucose level monitoring
Instruments and methods are described for performing non-invasive measurements of analyte levels and for monitoring, analyzing and regulating tissue status, such as tissue glucose levels.
Owner:MASIMO LAB INC
Method for advising patients concerning doses of insulin
A method for guiding a user to select a dose of insulin, including the steps of calculating a firsts pecific dose of insulin by applying information provided by the user to an insulin dose calculation algorithm, wherein such information includes at least the user's current blood glucose level and the user's desired blood glucose level, calculating at least a second specific dose of insulin that is different from the first specific dose, and presenting to the user a range of doses comprising at least two of the specific doses.
Owner:INSULET CORP
System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
An apparatus and method are provided for determining a patient's carbohydrate to insulin ratio (CIR) and insulin sensitivity factor (ISF), and using these values, along with values for current blood glucose level and deviation from target blood glucose level, for determining insulin dose in view of carbohydrate intake during a particular time period. The apparatus and method employ algorithms that can be implemented in any of a personal computer, personal data assistant, hand held computing device, blood glucose monitor, infusion pump, medication delivery pen, meter, calculator, among other therapeutic, diagnostic or informational devices used for managing a patient's blood glucose levels.
Owner:EMBECTA CORP
System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
Owner:EMBECTA CORP
Thermal quenching of tissue
InactiveUS7122029B2Selective heatingHeat buildDiagnosticsSurgical instruments for heatingCvd riskBlisters
Owner:NEW STAR LASERS
Transdermal delivery of antiparkinson agents
InactiveUS6929801B2Less complicated manufactureImprove dose uniformityCosmetic preparationsOrganic active ingredientsWhole bodyMedicine
The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.
Owner:ACRUX DDS
Medication device
A dispenser for medicaments comprises a first metering pump for insulin and a second metering pump for glucose or glucagon. A controller for both pumps is programmed to maintain a basal supply of insulin, and is responsive to a signal from a separate glucometer to dispense additional insulin or glucose or glucagon as appropriate.
Owner:RICHARDS CYNTHIA C
Analyte monitoring devices and methods therefor
Method and apparatus for performing a discrete glucose testing and bolus dosage determination including a glucose meter with bolus calculation function are provided.
Owner:ABBOTT DIABETES CARE INC
Accuracy of Continuous Glucose Sensors
InactiveUS20080314395A1Improve accuracy and reliabilityEasy CalibrationSurgeryDiagnostic recording/measuringGlucose sensorsComputer science
A method, apparatus, and a kit are capable of improving accuracy of CGS devices using dynamic outputs of continuous glucose sensors.
Owner:ABBOTT DIABETES CARE INC
Placental derived stem cells and uses thereof
The present invention features novel placental derived stem cells and provides methods and compositions for the therapeutic uses of placental derived stem cells or placental derived stem cells that have been induced to differentiate into a desired tissue type into a recipient host in amounts sufficient to result in production of the desired cell type, i.e., hepatic, pancreatic, neuronal, or nervous tissue.
Owner:UNIVERSITY OF PITTSBURGH
Method for controlling insulin pump using Bluetooth protocol
A method for controlling an insulin pump using the Bluetooth protocol. The method comprises allocating IDs to insulin pumps and blood sugar level measuring devices, respectively; checking, in a corresponding insulin pump, whether or not blood sugar level data is inputted from a blood sugar level measuring device having a corresponding ID; cumulating inputted data and judging whether or not abnormality occurs; generating a command to allow the insulin pump to operate as it is, when abnormality did not occur; generating a command to change an insulin injection amount of the insulin pump when abnormality occurred, and then, returning to the third step; and determining a system to be out of order when data is not inputted in the checking step, and generating an alarm so that a qualified person can visit a corresponding patient to have a trouble to be directly addressed.
Owner:CHOI SOO BONG
Rodent HER2 tumor model
The invention concerns HER<HIL><PDAT>2< / BOLD><PDAT>-transgenic non-human mammals, animal models for screening drug candidates for the treatment of diseases and disorders associated with the overexpression of HER<HIL><PDAT>2< / BOLD><PDAT>. In particular, the invention concerns animal models designed to test drug candidates for the treatment of HER<HIL><PDAT>2< / BOLD><PDAT>-overexpressing cancers, including breast cancer, that are not responding or poorly responding to current treatments.< / PTEXT>
Owner:SAN VALLEY SYST +1
Muscarinic receptor antagonists
Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Correction factor testing using frequent blood glucose input
An apparatus comprising a user interface configured to generate an electrical signal to begin determination of an effective correction factor when prompted by a user, an input configured to receive sampled blood glucose data of a patient that is obtained during a specified time duration, including a time duration after delivery of an initial insulin correction bolus, and a controller in electrical communication with the input and the user interface. The controller includes a correction factor module configured for determining an effective correction factor according to an amount of insulin in the initial insulin correction bolus and a decrease in the blood glucose level determined using the sampled blood glucose data. Other devices and methods are disclosed.
Owner:TANDEM DIABETES CARE INC
Stabilized insulin formulations
InactiveUS6852694B2Easy to separateBiocidePeptide/protein ingredientsINSULIN PREPARATIONSEndocrinology
The present invention is directed to stabilized insulin composition comprising a mixture of insulin species such as insulin and an insulin analog. As disclosed herein, insulin compositions comprising a mixture of insulin and insulin analog species form heterodimeric complexes having a greater stability than the homodimeric complexes formed in compositions comprising single insulin species. Consequently, the present invention provides methods for stabilizing insulin molecules, methods for identifying stable heterodimeric insulin complexes and stabilized insulin compositions.
Owner:MEDTRONIC MIMIMED INC
Method for expansion of stem cells
InactiveUS20060182724A1Increase oxygen contentAvoid clotsBiocideCosmetic preparationsCell culture mediaCell growth
A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.
Owner:RIORDAN NEIL H
Insulin pump for use in conjunction with mobile communication terminal capable of measuring blood glucose levels and network system for transmitting control information for insulin pump
InactiveUS20070060796A1Improve ease of useAccurate supplyDrug and medicationsMedical devicesKey pressingMotor drive
An insulin pump for use in conjunction with a mobile communication terminal capable of measuring a blood glucose level, and a network for transmitting control information for the insulin pump are disclosed. The insulin pump includes an external input port, an output port, memory, a key input unit, a control unit, and a motor driver. The external input port receives information on the amounts of insulin to be injected. The output port outputs information on the amounts of insulin injected. The memory stores the information on the amounts of insulin injected. The key input unit inputs the status of a user. The control unit extracts the information on the amounts of insulin to be injected from the memory. The motor drive operates a soft motor to supply insulin.
Owner:KIM YOON NYUN
Methods and compositions for organ and tissue functionality
Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.
Owner:DASK TECH
Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
ActiveUS20060008450A1Restore and enhance cardiac muscle functionRapid responseBiocideGenetic material ingredientsTissues typesEmbryo
Owner:RGT UNIV OF MINNESOTA
Cardiovascular compositions
InactiveUS20060135610A1Promote and maintain cardiovascular healthReduce adverse effectsBiocideDigestive systemCoronary artery diseaseCardiovascular health
Compositions that promote and / or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and / or maintain cardiovascular health through the prevention, stabilization, reversal and / or treatment of coronary artery disease and / or cerebrovascular disease. Such compositions may be used independently to promote and / or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and / or a health deteriorating condition.
Owner:DRAGTEK CORP
Blood sugar level measuring apparatus
InactiveUS20050187442A1Improve accuracyMaterial thermal conductivityBody temperature measurementBlood sugarOxygen saturation
Blood sugar levels are measured non-invasively based on temperature measurement. Non-invasively measured blood sugar level values obtained by a temperature measurement scheme are corrected by blood oxygen saturation and blood flow volume, thereby stabilizing the measurement data.
Owner:HITACHI LTD
Correction factor testing using frequent blood glucose input
An apparatus comprising a user interface configured to generate an electrical signal to begin determination of an effective correction factor when prompted by a user, an input configured to receive sampled blood glucose data of a patient that is obtained during a specified time duration, including a time duration after delivery of an initial insulin correction bolus, and a controller in electrical communication with the input and the user interface. The controller includes a correction factor module configured for determining an effective correction factor according to an amount of insulin in the initial insulin correction bolus and a decrease in the blood glucose level determined using the sampled blood glucose data. Other devices and methods are disclosed.
Owner:TANDEM DIABETES CARE INC
Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
InactiveUS20060233765A1BiocideMammal material medical ingredientsPhysiologyNeuro-degenerative disease
Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed.
Owner:DEPUY SYNTHES PROD INC
Metallopeptide compositions for treatment of sexual dysfunction
Owner:PALATIN TECH INC
Methods for identifying factors for differentiating definitive endoderm
Disclosed herein are methods of identifying one or more differentiation factors that are useful for differentiating cells in a cell population comprising definitive endoderm cells into cells which are capable of forming tissues and / or organs that are derived from the gut tube.
Owner:VIACYTE INC
System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
An apparatus and method are provided for determining a patient's carbohydrate to insulin ratio (CIR) and insulin sensitivity factor (ISF), and using these values, along with values for current blood glucose level and deviation from target blood glucose level, for determining insulin dose in view of carbohydrate intake during a particular time period. The apparatus and method employ algorithms that can be implemented in any of a personal computer, personal data assistant, hand held computing device, blood glucose monitor, infusion pump, medication delivery pen, meter, calculator, among other therapeutic, diagnostic or informational devices used for managing a patient's blood glucose levels.
Owner:EMBECTA CORP
Injectable compositions of nanoparticulate immunosuppressive compounds
InactiveUS20060210638A1Improve complianceImprove efficacyPowder deliveryBiocideDepressantCompound (substance)
The invention is directed to an injectable nanoparticulate immunosuppressant composition for the formation of a subcutaneous or intramuscular depot. The invention is also directed to an injectable composition of nanoparticulate tacrolimus and / or sirolimus which eliminates the need to use polyoxyl 60 hydrogenated castor oil (HCO-60) and / or polysorbate 80 as a solubilizer. This invention further discloses a method of making an injectable nanoparticulate tacrolimus and / or sirolimus composition and is also directed to methods of treatment using the injectable nanoparticulate formulations comprising tacrolimus, sirolimus, or combination thereof for a subcutaneous or intramuscular depot for the prophylaxis of organ rejection and for the treatment of psoriasis or other immune diseases
Owner:ELAN PHRMA INT LTD
Chronic treatment regimen using glucagon-like insulinotropic peptides
InactiveUS7259233B2Avoids and minimizes side effectPeptide/protein ingredientsImmunoglobulinsDiseasePeptide
The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.
Owner:ELI LILLY & CO
Humanized antibodies that recognize beta amyloid peptide
InactiveUS7179892B2Reduce the burden onReducing the neuritic dystrophyNervous disorderGenetically modified cellsHumanized antibodyΒ amyloid peptide
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
Owner:WYETH LLC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com